fbpx

Archive: March, 2021

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing …

Read More

Thousand Oaks, California-based Amgen is acquiring Seattle-based Rodeo Therapeutics. Rodeo develops small-molecule drugs that promote regeneration and repair of various tissues….

Read More

The National Institute for Health and Care Excellence (NICE) has recommended Sobi’s Kineret for the first-line treatment of the rare inflammatory disorder Still’s …

Read More

The European Commission (EC) has approved Roche’s spinal muscular atrophy (SMA) treatment Evrysdi for use in patients aged two months and older….

Read More

Just over a year after Wave Life Sciences cut staffers, threw out a Duchenne muscular dystrophy med and saw its Huntington’s disease drug …

Read More

Merck is having a very busy week. Here’s today’s news. The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) …

Read More

A new coronavirus strain has been identified in Israel, the Health Ministry said on Tuesday, and the Pfizer/BioNTech vaccine, used primarily in a …

Read More

ZURICH (Reuters) – Novartis is laying off 400 people and closing a U.S. gene therapy location that it bought only two years ago …

Read More

TOKYO, Japan I March 26, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today the Committee …

Read More

A new type of cancer immunotherapy, when added to Bristol Myers Squibb’s drug Opdivo, succeeded in a late-stage clinical study of people with …

Read More

GSK–VirGlaxoSmithKline and Vir Biotechnology have filed for emergency use authorization (EUA) for VIR-7831 (GSK4182136), a dual-action SARS-CoV-2 monoclonal antibody.

VIR-7831 …

Read More

The FDA has approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior …

Read More

X
Send a message
Request a call

    * Required fields

    By submitting this form you confirm that you have read and accepted our privacy policy. Your data will be used exclusively for this purpose.

      * Required fields

      By submitting this form you confirm that you have read and accepted our privacy policy. Your data will be used exclusively for this purpose.

      X